[ { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U#pubinfo", "@graph": [ { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U#sig", "http://purl.org/nanopub/x/hasAlgorithm": [ { "@value": "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey": [ { "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature": [ { "@value": "BFfWhquQcweGbbmG3CXU8oZvIQBybUOWUtk1EdkcsogC6s9C+k/IT4m/+KuuGGMX6yntISm/TM4HeF/Mq9z1j8eNiyFwgSt+4+qS0PTSd1lbl7X+yyDUFurTwqvhxKRwfCjQ3pjFBSsbIZTmGOm5XFI+m5SNYm0vPp5Jowu0GTU=" } ], "http://purl.org/nanopub/x/hasSignatureTarget": [ { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U" } ] }, { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U", "http://purl.org/dc/terms/created": [ { "@value": "2021-08-23T18:57:43.341+02:00", "@type": "http://www.w3.org/2001/XMLSchema#dateTime" } ], "http://purl.org/dc/terms/creator": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [ { "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [ { "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [ { "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] } ] }, { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U#Head", "@graph": [ { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U", "http://www.nanopub.org/nschema#hasAssertion": [ { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance": [ { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo": [ { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U#pubinfo" } ], "@type": [ "http://www.nanopub.org/nschema#Nanopublication" ] } ] }, { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U#assertion", "@graph": [ { "@id": "http://purl.obolibrary.org/obo/DOID_1588", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U#association", "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [ { "@id": "http://purl.obolibrary.org/obo/DOID_1588" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [ { "@id": "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [ { "@id": "https://identifiers.org/drugbank:DB01109" } ], "@type": [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ], "http://www.w3.org/2000/01/rdf-schema#label": [ { "@value": "\"The use of Heparin Sodium in 0.45% Sodium Chloride Injection or Heparin Sodium in 5% Dextrose Injection is contraindicated in patients with the following conditions: History of Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT) [see Warnings and Precautions ( 5.3 Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see Adverse Reactions ( 6.1 In whom suitable blood coagulation tests -- e.g., the whole blood clotting time, partial thromboplastin time, etc., -- cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin) [see Warnings and Precautions ( 5.5 An uncontrolled bleeding state [see Warnings and Precautions ( 5.2 History of Heparin-Induced Thrombocytopenia (HIT) and Heparin-Induced Thrombocytopenia and Thrombosis (HITT) ( 4 Known hypersensitivity to heparin or pork products ( 4 In whom suitable blood coagulation tests cannot be performed at appropriate intervals ( 4\"" } ], "https://w3id.org/biolink/vocab/provided_by": [ { "@id": "https://w3id.org/um/NeuroDKG" } ], "https://w3id.org/biolink/vocab/relation": [ { "@id": "https://schema.org/MedicalContraindication" } ] }, { "@id": "https://identifiers.org/drugbank:DB01109", "https://w3id.org/biolink/vocab/category": [ { "@id": "https://w3id.org/biolink/vocab/Drug" } ] } ] }, { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U#provenance", "@graph": [ { "@id": "http://purl.org/np/RAT-7sbTFVfj7swAEk5DX7O8nCKBJSIcS0E9OoXwNDn8U#assertion", "http://www.w3.org/ns/prov#wasAttributedTo": [ { "@id": "https://orcid.org/0000-0002-1468-3557" } ] } ] } ]